Pinion Immunotherapeutics
Exhibitor
Pinion Immunotherapeutics develops mRNA-based immunotherapies for diseases driven by chronic viral infections. Its lead candidate, ARV-2001, is expected to enter a Phase I/II trial in Q2 2026 for HPV16-related precancer (cHSIL).We are looking for investors to follow our tranche 1 lead investor with 1-4 M for a total of 7.5M and our tranche 2 up to 9M for a total of 12.5M. Pinion is also advancing programs targeting HSV- and EBV-associated diseases, including genital herpes, periodontitis, and multiple sclerosis and would welcome investment or partnership for its pipeline.
Created by
Terrapinn is proud to be a member of isla.
Working together to build sustainable events